Livzon Pharmaceutical (01513.HK): Tiange Dingxuan Granules receives the Drug Clinical Trial Approval Notice

Zhitong Finance APP News, Livzon Pharmaceutical (01513.HK) announced that recently, the company's subsidiary Sichuan Guangda Pharmaceutical Co., Ltd. (Sichuan Guangda) received the "Drug Clinical Trial Approval Notice" (Notice No.: 2026LP03296) approved and issued by the National Medical Products Administration, agreeing to Sichuan Guangda's application for Tiange Dingxuan Granules (this product) to conduct clinical trials for "vestibular migraine (wind-phlegm with blood stasis, disturbing the clear orifices syndrome)."